title: A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.
abstract: CONCLUSIONS
  This superselective intra-arterial intervention technique enabled us to administer a higher dose of cisplatinum to the local lesion with a lower incidence of adverse issues by use of neutralizer, compared with the conventional methods.
  
  
  OBJECTIVE
  A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer. However, there is still much controversy with regard to the optimum treatment to obtain better local control and acceptable preservation of shape and function. Since 2001, we have performed superselective intra-arterial infusion chemotherapy in combination with radiotherapy and surgery aiming at a higher local control rate.
  
  
  METHODS
  This was a review of prospective collected data. The therapeutic design consisted of weekly intra-arterial infusion of high dose CDDP with concomitant radiotherapy and planned surgery performed during chemo-radiation therapy. From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.
  
  
  RESULTS
  The local response rate with this combined therapy was 85.7%. Overall survival rates at 1 and 2 years were 78.6% and 56.2%, respectively, with median follow-up of 25.5 months.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fujishiro
authors.forename: Kazunari
authors.initials: K
authors.lastname: Nakao
authors.forename: Kenta
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ebihara
authors.forename: Naoki
authors.initials: N
authors.lastname: Nakamura
authors.forename: Harushi
authors.initials: H
authors.lastname: Mori
authors.forename: Naoto
authors.initials: N
authors.lastname: Hayashi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Asakage
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008279:Magnetic Resonance Imaging; D008297:Male; D008443:Maxillary Sinus / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin